Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 27 Sept 2021

Goel Amit, Bhadauria Dharmendra S, Kaul Anupma, Verma Abhai, Tiwari Prachi, Rungta Sumit, Rai Praveer, Gupta Amit, Aggarwal Rakesh

Abstract excerpt

BACKGROUND: Sofosbuvir is not recommended in persons with estimated glomerular filtration rate (eGFR) <30 mL/min. We report the results of treatment with an off-label 8-week regimen of daclatasvir and half-dose sofosbuvir in patients with acute infection with hepatitis C virus ( HCV) and eGFR <30 mL/min. METHODS: Clinic records were searched to identify treatment-naïve, noncirrhotic adults with acute hepatitis C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Imidazoles

Share to Pyrrolidines

Share to Renal Insufficiency

Share to Sofosbuvir

Share to Valine

Source

Identifiers

PMID: 33097949
DOI: 10.1093/ndt/gfaa187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.PMID 33097949Read ↗

Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.Semantic proximity Read ↗

Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.Semantic proximity Read ↗

HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.Semantic proximity Read ↗

Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.Semantic proximity Read ↗

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.Semantic proximity Read ↗

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.Semantic proximity Read ↗

Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.Semantic proximity Read ↗

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Semantic proximity Read ↗

Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis.Semantic proximity Read ↗

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.